Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Regeneron Pharmaceuticals (NASDAQ:REGN) operates within the biotechnology sector and is listed on Biggest Companies on Nasdaq ...

Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

STORY: U.S. stocks ended a choppy session mixed on Friday, with the Dow up marginally, the S&P 500 flat and the Nasdaq down ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.